RARE – Ultragenyx Pharmaceutical Inc.
Float Short %
10.03
Margin Of Safety %
Put/Call OI Ratio
0.73
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
3.98
Price
22.73
Target Price
56.55
Analyst Recom
1.18
Performance Q
-30.8
Upside
-999.6%
Beta
0.17
Ticker: RARE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | RARE | 24.21 | 0.96 | 0.97 | 30403 |
| 2026-01-26 | RARE | 24.31 | 0.95 | 0.10 | 30304 |
| 2026-01-27 | RARE | 24.61 | 0.94 | 0.22 | 30403 |
| 2026-01-28 | RARE | 24.43 | 0.94 | 1.25 | 30428 |
| 2026-01-29 | RARE | 24.27 | 0.94 | 7.21 | 30415 |
| 2026-01-30 | RARE | 24.02 | 0.94 | 0.05 | 30314 |
| 2026-02-02 | RARE | 24.75 | 0.93 | 0.05 | 30448 |
| 2026-02-03 | RARE | 24.8 | 0.92 | 1.66 | 30541 |
| 2026-02-04 | RARE | 24.7 | 0.91 | 0.73 | 30403 |
| 2026-02-05 | RARE | 23.81 | 0.91 | 54.22 | 30402 |
| 2026-02-06 | RARE | 24.67 | 1.00 | 0.06 | 31773 |
| 2026-02-09 | RARE | 23.87 | 0.92 | 0.42 | 31007 |
| 2026-02-10 | RARE | 24.19 | 0.92 | 22.37 | 31012 |
| 2026-02-11 | RARE | 23.86 | 1.09 | 0.08 | 34251 |
| 2026-02-12 | RARE | 23.51 | 1.08 | 0.74 | 34452 |
| 2026-02-13 | RARE | 20.52 | 1.07 | 0.37 | 34572 |
| 2026-02-17 | RARE | 20.19 | 1.02 | 1.53 | 33817 |
| 2026-02-18 | RARE | 20.45 | 0.82 | 6.20 | 30453 |
| 2026-02-19 | RARE | 21.83 | 0.83 | 0.02 | 30680 |
| 2026-02-20 | RARE | 22.73 | 0.73 | 0.01 | 32531 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | RARE | 24.20 | 19.6 | - | -5.78 |
| 2026-01-26 | RARE | 24.31 | 19.6 | - | -5.78 |
| 2026-01-27 | RARE | 24.60 | 19.6 | - | -5.78 |
| 2026-01-28 | RARE | 24.41 | 19.6 | - | -5.78 |
| 2026-01-29 | RARE | 24.25 | 19.6 | - | -5.78 |
| 2026-01-30 | RARE | 24.06 | 19.6 | - | -5.78 |
| 2026-02-02 | RARE | 24.75 | 19.6 | - | -5.78 |
| 2026-02-03 | RARE | 24.79 | 19.6 | - | -5.78 |
| 2026-02-04 | RARE | 24.70 | 19.6 | - | -5.78 |
| 2026-02-05 | RARE | 23.82 | 19.6 | - | -5.78 |
| 2026-02-06 | RARE | 24.68 | 19.6 | - | -5.78 |
| 2026-02-09 | RARE | 23.87 | 19.6 | - | -5.78 |
| 2026-02-10 | RARE | 24.20 | 19.6 | - | -5.78 |
| 2026-02-11 | RARE | 23.86 | 15.7 | - | -5.78 |
| 2026-02-12 | RARE | 23.52 | 15.7 | - | -5.78 |
| 2026-02-13 | RARE | 20.50 | 15.7 | - | -5.78 |
| 2026-02-17 | RARE | 20.18 | 17.0 | - | -5.78 |
| 2026-02-18 | RARE | 20.47 | 17.0 | - | -5.78 |
| 2026-02-19 | RARE | 21.83 | 14.9 | - | -5.78 |
| 2026-02-20 | RARE | 22.73 | 14.9 | - | -3.90 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | RARE | -0.25 | 3.30 | 8.93 |
| 2026-01-26 | RARE | -0.25 | 3.10 | 8.93 |
| 2026-01-27 | RARE | -0.25 | 3.10 | 8.93 |
| 2026-01-28 | RARE | -0.25 | 3.10 | 9.87 |
| 2026-01-29 | RARE | -0.25 | 3.10 | 9.87 |
| 2026-01-30 | RARE | -0.25 | 3.10 | 9.87 |
| 2026-02-02 | RARE | -0.25 | 3.31 | 9.87 |
| 2026-02-03 | RARE | -0.30 | 3.31 | 9.87 |
| 2026-02-04 | RARE | -0.30 | 3.31 | 9.87 |
| 2026-02-05 | RARE | -0.30 | 3.31 | 9.87 |
| 2026-02-06 | RARE | -0.30 | 3.31 | 9.87 |
| 2026-02-09 | RARE | -0.30 | 3.96 | 9.87 |
| 2026-02-10 | RARE | -0.30 | 3.96 | 9.87 |
| 2026-02-11 | RARE | -0.30 | 3.96 | 10.13 |
| 2026-02-12 | RARE | -0.30 | 3.96 | 10.13 |
| 2026-02-13 | RARE | -0.30 | 3.96 | 10.13 |
| 2026-02-17 | RARE | -0.30 | 0.86 | 10.12 |
| 2026-02-18 | RARE | -0.30 | 0.86 | 10.12 |
| 2026-02-19 | RARE | -0.30 | 0.86 | 10.12 |
| 2026-02-20 | RARE | -0.30 | 0.86 | 10.03 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-1.34
Avg. EPS Est. Next Quarter
-1.07
Insider Transactions
-0.3
Institutional Transactions
0.86
Beta
0.17
Average Sales Estimate Current Quarter
165
Average Sales Estimate Next Quarter
181
Fair Value
Quality Score
27
Growth Score
49
Sentiment Score
2
Actual DrawDown %
84.7
Max Drawdown 5-Year %
-86.7
Target Price
56.55
P/E
Forward P/E
PEG
P/S
3.26
P/B
P/Free Cash Flow
EPS
-5.84
Average EPS Est. Cur. Y
-3.9
EPS Next Y. (Est.)
0.08
Target Price Estimates Raised
Target Price Estimates Lowered
2
Profit Margin
-85.54
Relative Volume
0.78
Return on Equity vs Sector %
-6359.7
Return on Equity vs Industry %
-6342.2
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.26
EBIT Estimation
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1371
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading